A role for local inflammation in the formation of drusen in the aging eye

American Journal of Ophthalmology

Volumn 134, Issue 3, 2002, Pages 411-431

  Anderson, Don H ^a   Mullins, Robert F ^b   Hageman, Gregory S ^b   Johnson, Lincoln V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID P COMPONENT; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10; C REACTIVE PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBRINOGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; THROMBIN; VITRONECTIN;

ADOLESCENT; ADULT; AGED; AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BIOGENESIS; BRUCH MEMBRANE; CHOROID; COMPLEMENT ACTIVATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUSEN; ELECTRON MICROSCOPY; EYE INFLAMMATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULE; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINA MACULA DEGENERATION; REVIEW; RISK FACTOR;

EID: 0036741098     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01624-0     Document Type: Article

References (108)

1. Coats G. The structure of the membrane of Bruch and its relation to the formation of colloid excrescences. Royal London Ophthalm Hosp Rep. XVI:1905;164-178.
2. Hogan M.J. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol. 76:1972;64-80.
3. Killingsworth M.C. Age-related components of Bruch's membrane in the human eye. Graefes Arch Clin Exp Ophthalmol. 225:1987;406-412.
4. Bressler S.B., Maguire M.G., Bressler N.M., Fine S.L., The Macular Photocoagulation Study Group. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol. 108:1990;1442-1447.
5. Pauleikhoff D., Barondes M.J., Minassian D., Chisholm I.H., Bird A.C. Drusen as risk factors in age-related macular disease. Am J Ophthalmol. 109:1990;38-43.
6. Vinding T. Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol. 68:1990;410-414.
7. Bressler N.M., Silva J.C., Bressler S.B., Fine S.L., Green W.R. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina. 14:1994;130-142.
8. Stone E.M., Sheffield V.C., Hageman G.S. Molecular genetics of age-related macular degeneration. Hum Mol Genet. 10:2001;2285-2292.
9. Gass J.D. Drusen and disciform macular detachment and degeneration. Trans Am Ophthalmol Soc. 70:1973;409-436.
10. Teeters V.W., Bird A.C. The development of neovascularization of senile disciform macular degeneration. Am J Ophthalmol. 76:1973;1-18.
11. Klein R., Klein B.E., Linton K.L., DeMets D.L. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol. 137:1993;190-200.
12. Holz F.G., Wolfensberger T.J., Piguet B., et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology. 101:1994;1522-1528.
13. Sarraf D., Gin T., Yu F., Brannon A., Owens S.L., Bird A.C. Long-term drusen study. Retina. 19:1999;513-519.
14. Donders F.C. Beitrage zur pathologischen Anatomie des Auges. Graefes Arch Clin Exp Ophthalmol. 1:1854;106-118.
15. Muller H. Anatomische beitrage zur ophthalmologie. Albrecht von Graefe Archiv fur Ophthalmol. 2:1856;1-69.
16. Friedman E., Smith T.R., Kuwabara T. Senile choroidal vascular patterns and drusen. Arch Ophthalmol. 69:1963;220-230.
17. Fine B.S. Lipoidal degeneration of the retinal pigment epithelium. Am J Ophthalmol. 91:1981;469-473.
18. Farkas T.G., Sylvester V., Archer D., Altona M. The histochemistry of drusen. Am J Ophthalmol. 71:1971;1206-1215.
19. Farkas T.G., Sylvester V., Archer D. The ultrastructure of drusen. Am J Ophthalmol. 71:1971;1196-1205.
20. Ishibashi T., Patterson R., Ohnishi Y., Inomata H., Ryan S.J. Formation of drusen in the human eye. Am J Ophthalmol. 101:1986;342-353.
21. Ishibashi T., Sorgente N., Patterson R., Ryan S.J. Pathogenesis of drusen in the primate. Invest Ophthalmol Vis Sci. 27:1986;184-193.
22. Burns R.P., Feeney-Burns L. Clinico-morphologic correlations of drusen of Bruch's membrane. Trans Am Ophthalmol Soc. 78:1980;206-225.
23. Young R.W. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 31:1987;291-306.
24. Newsome D.A., Hewitt A.T., Huh W., Robey P.G., Hassell J.R. Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body. Am J Ophthalmol. 104:1987;373-381.
25. van der Schaft T.L., Mooy C.M., de Bruijn W.C., de Jong P.T. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol. 77:1993;657-661.
26. Loeffler K., Edward D., Tso M. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci. 36:1995;24-31.
27. Fariss R.N., Apte S.S., Olsen B.R., Iwata K., Milam A.H. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol. 150:1997;323-328.
28. Loeffler K.U., Mangini N.J. Immunolocalization of ubiquitin and related enzymes in human retina and retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol. 235:1997;248-254.
29. Pauleikhoff D., Zuels S., Sheraidah G.S., Marshall J., Wessing A., Bird A.C. Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology. 99:1992;1548-1553.
30. Hageman G.S., Mullins R.F., Clark W.G., Johnson L.V., Anderson D.H. Drusen share molecular constituents common to atherosclerotic, elastotic and amyloid deposits. Invest Ophthalmol Vis Sci. 36:1995;S432.
31. Hageman G.S., Mullins R.F., Russell S.R., Johnson L.V., Anderson D.H. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J. 13:1999;477-484.
32. Mullins R.F., Russell S.R., Anderson D.H., Hageman G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14:2000;835-846.
33. Mullins R.F., Aptsiauri N., Hageman G.S. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye. 15:2001;390-395.
34. Abdelsalam A., Del Priore L., Zarbin M.A. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol. 44:1999;1-29.
35. Green W.R. Histopathology of age-related macular degeneration. Mol Vis. 5:1999;27.
36. Bressler N.M., Bressler S.B., Fine S.L. Neovascular (exudative) age-related macular degeneration. Ryan S.J. Retina. 3rd ed. 2001;1101-1135 Mosby St. Louis.
37. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 20:2001;705-732.
38. Penfold P.L., Madigan M.C., Gillies M.C., Provis J.M. Immunological and aetiological aspects of macular degeneration. Progress in retinal research. 2001;385-414 Elsevier Science Ltd London.
39. Sarks S.H., Sarks J.P. Age-related maculopathy: non-neovascular age-related maculation degeneration and the evolution of geographic atrophy. Ryan S.J. Retina. 3rd ed. 2001;1064-1097 Mosby St. Louis.
40. Mullins R.F., Johnson L.V., Anderson D.H., Hageman G.S. Characterization of drusen-associated glycoconjugates. Ophthalmology. 104:1997;288-294.
41. Anderson D.H., Ozaki S., Nealon M., et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 131:2001;767-781.
42. Johnson L.V., Ozaki S., Staples M.K., Erickson P.A., Anderson D.H. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 70:2000;441-449.
43. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 73:2001;887-896.
44. Russell S.R., Mullins R.F., Schneider B.L., Hageman G.S. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol. 129:2000;205-214.
45. Trump B.F., Berezesky I.K., Chang S.H., Phelps P.C. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol. 25:1997;82-88.
46. Mori S., Sternberger N.H., Herman M.M., Sternberger L.A. Leakage and neuronal uptake of serum protein in aged and Alzheimer brains. A postmortem phenomenon with antemortem etiology. Lab Invest. 64:1991;345-351.
47. Marshall J., Hussain A.A., Starita C., Moore D.J., Patmore A.L. Aging and Bruch's membrane. Marmor M.F. Wolfensberg T.J. The retinal pigment epithelium. Function and disease. 1998;669-692 Oxford University Press New York.
48. Sarks S.H., Arnold J.J., Killingsworth M.C., Sarks J.P. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol. 83:1999;358-368.
49. Ong D.E., Davis J.T., O'Day W.T., Bok D. Synthesis and secretion of retinal-binding protein and transthyretin by cultured retinal pigment epithelium. Biochemistry. 33:1994;1835-1842.
50. Phelps P.C., Smith M.W., Trump B.F. Cytosolic ionized calcium and bleb formation after acute cell injury of cultured rabbit renal tubule cells. Lab Invest. 60:1989;630-642.
51. Sheraidah G., Steinmetz R., Maguire J., Pauleikhoff D., Marshall J., Bird A.C. Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology. 100:1993;47-51.
52. Curcio C.A., Millican C.L., Bailey T., Kruth H.S. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. 42:2001;265-274.
53. Haimovici R., Gantz D.L., Rumelt S., Freddo T.F., Small D.M. The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci. 42:2001;1592-1599.
54. Malek G., Guidry C., Bailey T.M., Curcio C.A. Apolipoprotein B (Apo B) and lipid localization in Bruch's membrane. Invest Ophthalmol Vis Sci. 39:1998;S369.
55. Anderson D.H., Hageman G.S., Neitz M., et al. Local cellular sources of drusen-associated molecules. Invest Ophthalmol Vis Sci. 39:1998;S369.
56. Klaver C.C., Kliffen M., van Duijn C.M., et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 63:1998;200-206.
57. Bird J.C., Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Soc Ophthalmol UK. 105:1986;674-682.
58. Mahley R.W., Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol. 10:1999;207-217.
59. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17:1994;525-530.
60. Davignon J., Cohn J.S., Mabile L., Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta. 286:1999;115-143.
61. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
62. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA. 92:1995;4725-4727.
63. Souied E.H., Benlian P., Amouyel P., et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol. 125:1998;353-359.
64. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:1991;163-166.
65. Gallo G., Wisniewski T., Choi-Miura N.H., Ghiso J., Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol. 145:1994;526-530.
66. McGeer P.L., Klegeris A., Walker D.G., Yasuhara O., McGeer E.G. Pathological proteins in senile plaques. Tohoku J Exp Med. 174:1994;269-277.
67. Babaev V.R., Dergunov A.D., Kurashvili L.R., et al. The localization of apoprotein E in the normal human aortic wall and in atherosclerosis. Arkh Patol. 52:1990;52-56.
68. Farquhar M.G. Molecular analysis of the pathological autoimmune antigens of Heymann nephritis. [comment] Am J Pathol. 148:1996;1331-1337.
69. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
70. Morgan B.P. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci. 32:1995;265-298.
71. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21:2000;383-421.
72. Baumann H., Gauldie J. The acute phase response. Immunol Today. 15:1994;74-80.
73. Anderson D., Hageman G., Mullins R., et al. Vitronectin gene expression in the adult human retina. Invest Ophthalmol Vis Sci. 40:1999;3305-3315.
74. Ozaki S., Johnson L.V., Mullins R.F., Hageman G.S., Anderson D.H. The human retina and retinal pigment epithelium are abundant sources of vitronectin mRNA. Biochem Biophys Res Commun. 258:1999;524-529.
75. Morgan B.P. The complement system: an overview. Methods Mol Biol. 150:2000;1-13.
76. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 49:2000;171-186.
77. Johnson L.V., Leiter W.P., Staples M.K., Anderson D.H. Evidence that drusen formation is a byproduct of complement-mediated attack on the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 42:2001;S944.
78. Hugo F., Kramer S., Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods. 99:1987;243-251.
79. Niculescu F., Hugo F., Rus H.G., Vlaicu R., Bhakdi S. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin Exp Immunol. 69:1987;477-483.
80. Morgan B.P., Daniels R.H., Watts M.J., Williams B.D. In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium. Clin Exp Immunol. 73:1988;467-472.
81. Morgan B.P. Non-lethal complement-membrane attack on human neutrophils: transient cell swelling and metabolic depletion. Immunology. 63:1988;71-77.
82. Strunk R.C., Eidlen D.M., Mason R.J. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest. 81:1988;1419-1426.
83. Morgan B.P., Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol. 107:1997;1-7.
84. Shen Y., Li R., McGeer E.G., McGeer P.L. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769:1997;391-395.
85. Morgan B.P. Regulation of the complement membrane attack pathway. Crit Rev Immunol. 19:1999;173-198.
86. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 73:2001;887-896.
87. Gewurz H., Ying S.C., Jiang H., Lint T.F. Nonimmune activation of the classical complement pathway. Behring Inst Mitt. 1993;138-147.
88. Schultz D.R., Arnold P.I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 20:1990;129-147.
89. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 19:1999;2348-2354.
90. Ishibashi T., Murata T., Hangai M., et al. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 116:1998;1629-1632.
91. Farboud B., Aotaki-Keen A., Miyata T., Hjelmelund L.M., Handa J.T. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Mol Vis. 5:1999;11.
92. Kerjaschki D., Neale T.J. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). [Editorial] J Am Soc Nephrol. 7:1996;2518-2526.
93. Kerjaschki D. The immune complex pathogenesis of experimental membranous glomerulopathy (Heymann nephritis) and its significance in human glomerular disease. Verh Dtsch Ges Pathol. 73:1989;24-35.
94. Johnson L.V., Staples M.K., de los Rios M.A., et al. Inflammation and the immune response in age-related macular degeneration. Exp Eye Res. 67:Supp 1 1998;S102.
95. Penfold P.L., Provis J.M., Furby J.H., Gatenby P.A., Billson F.A. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 228:1990;270-274.
96. Gurne D.H., Tso M.O., Edward D.P., Ripps H. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology. 98:1991;602-607.
97. Forrester J.V., McMenamin P.G., Liversidge J., Lumsden L. Dendritic cells and "dendritic" macrophages in the uveal tract. Adv Exp Med Biol. 329:1993;599-604.
98. Forrester J.V., McMenamin P.G., Holthouse I., Lumsden L., Liversidge J. Localization and characterization of major histocompatibility complex class II-positive cells in the posterior segment of the eye: implications for induction of autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 35:1994;64-77.
99. Jiang H.R., Lumsden L., Forrester J.V. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 40:1999;3177-3185.
100. Detrick B., Rodrigues M., Chan C.C., Tso M.O., Hooks J.J. Expression of HLA-DR antigen on retinal pigment epithelial cells in retinitis pigmentosa. Am J Ophthalmol. 101:1986;584-590.
101. Liversidge J.M., Sewell H.F., Forrester J.V. Human retinal pigment epithelial cells differentially express MHC class II (HLA, DP, DR and DQ) antigens in response to in vitro stimulation with lymphokine or purified IFN-gamma. Clin Exp Immunol. 73:1988;489-494.
102. Mata N.L., Weng J., Travis G.H. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci USA. 97:2000;7154-7159.
103. Gass J.D. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol. 75:1971;580-608.
104. Bressler N.M., Munoz B., Maguire M.G., et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Arch Ophthalmol. 113:1995;301-308.
105. Duvall J., Tso M.O. Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. Arch Ophthalmol. 103:1985;694-703.
106. Bhakdi S., Dorweiler B., Kirchmann R., et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low-density lipoprotein to an atherogenic moiety. J Exp Med. 182:1995;1959-1971.
107. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
108. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 20:2000;5709-5714.